| Literature DB >> 34976297 |
Xia Li1, Dianxuan Guo1, Youdong Hu1, Ying Chen1.
Abstract
Oxidative stress and inflammatory response are the main pathogenic pathways in atherosclerosis stenosis. This study is aimed at evaluating the roles of oxidative stress and inflammatory response in coexistent right carotid artery severe stenosis and severe multivessel coronary artery stenosis in elderly patients. Circulating levels of total oxidant status (TOS), lipid hydroperoxide (LHP), 8-isoprostane (8-IP), malondialdehyde (MDA), monocyte chemotactic protein-4 (MCP-4), amyloid A (AA), high-sensitivity C-reactive protein (hs-CRP), and tumor necrosis factor-α (TNF-α) were measured by standardised laboratory test methods. Markers of oxidative stress and inflammatory response: levels of TOS, LHP, 8-IP, MDA, MCP-4, AA, hs-CRP, and TNF-α, were increased (P < 0.001) in elderly patient. These results suggested that oxidative stress and inflammatory response may be involved in carotid artery severe stenosis and severe multivessel coronary artery stenosis and measuring oxidative stress and inflammation biomarkers may also be a promising step in the development of an effective method for monitoring the severity of right carotid artery stenosis and multivessel coronary artery stenosis in elderly patients.Entities:
Mesh:
Year: 2021 PMID: 34976297 PMCID: PMC8716240 DOI: 10.1155/2021/2976447
Source DB: PubMed Journal: Oxid Med Cell Longev ISSN: 1942-0994 Impact factor: 6.543
Baseline characteristics of patients with RCCAS, RECAS, RICAS, RCCAS+RECAS+RICAS, and RCCAS+RECAS+RICAS+coronary artery lesions.
| CON ( | No carotid stenosis ( | RCCAS ( | RECAS ( | RICAS ( | RCCAS+RECAS+RICAS ( | RCCAS+RECAS+RICAS+coronary artery stenosis ( |
| |
|---|---|---|---|---|---|---|---|---|
| Gender | ||||||||
| Male, | 31 (51) | 29 (52) | 83 (49) | 82 (51) | 83 (49) | 82 (49) | 79 (51) | 0.41 |
| Female, | 30 (49) | 27 (48) | 84 (51) | 80 (49) | 84 (51) | 83 (51) | 76 (49) | 0.43 |
| Age (years) | 65.1 ± 13.0 | 65.8 ± 13.2 | 64.2 ± 13.4 | 65.1 ± 14.0 | 63.8 ± 14.4 | 62.2 ± 15.1 | 76.6 ± 15.3 | 0.32 |
| CAD, | 0 | 17 (30) | 83 (49) | 81 (50) | 84 (50) | 82 (49) | 77 (50) | 0.41 |
| Hypertension, | 0 | 15 (27) | 35 (21) | 54 (33) | 60 (35) | 54 (32) | 47 (30) | 0.07 |
| Diabetes mellitus, | 0 | 10 (18) | 33 (19) | 30 (18) | 33 (20) | 32 (19) | 30 (19) | 0.12 |
| History of stroke, | 0 | 0 | 9 (5) | 8 (5) | 7 (4) | 8 (4) | 9 (5) | 0.06 |
| Current smoking, | 0 | 6 (11) | 42 (25) | 29 (17) | 40 (23) | 29 (17) | 40 (25) | 0.07 |
| Current drinking, | 0 | 0 | 9 (5) | 11 (7) | 9 (4) | 12 (7) | 9 (5) | 0.06 |
| Regular exercise, | 5 (8) | 4 (7) | 7 (4) | 5 (3) | 6 (3) | 4 (2) | 9 (6) | 0.17 |
| Myocardial infarction, | 0 | 0 | 0 | 0 | 0 | 0 | 11 (7) | 0.14 |
| Dizziness, | 0 | 0 | 6 (3) | 3 (1) | 4 (2) | 7 (4) | 4 (2) | 0.10 |
| Memory impairment, | 0 | 0 | 25 (15) | 21 (13) | 17 (10) | 20 (12) | 9 (6) | 0.27 |
| Amaurosis fugax, | 0 | 0 | 16 (9) | 13 (8) | 12 (7) | 11 (6) | 10 (6) | 0.16 |
| Cognitive impairment, | 0 | 0 | 10 (5) | 7 (4) | 6 (3) | 8 (4) | 7 (4) | 0.09 |
| Angina pectoris, | 0 | 0 | 0 | 0 | 0 | 0 | 20 (13) | 0.14 |
CON: control; RCCAS: right common carotid artery stenosis; RECAS: right external carotid artery stenosis; RICAS: right internal carotid artery stenosis; CAD: coronary artery disease.
Levels of biomarkers in patients with RCCAS.
| CON ( | No carotid stenosis ( | MI-RCCAS ( | MO-RCCAS ( | SE-RCCAS ( | |
|---|---|---|---|---|---|
| TOS ( | 7.3 ± 0.7 | 7.4 ± 0.7 | 7.8 ± 1.5∗ | 8.3 ± 0.8∗∗ | 9.1 ± 0.9∗∗∗ |
| LHP ( | 5.8 ± 0.6 | 5.9 ± 0.6 | 6.7 ± 0.7∗ | 7.9 ± 0.8∗∗ | 8.7 ± 0.9∗∗∗ |
| 8-IP (pg/mL) | 45.2 ± 4.5 | 45.0 ± 4.4 | 56.2 ± 5.6∗ | 68.8 ± 6.9∗∗ | 77.4 ± 7.6∗∗∗ |
| MDA (nmol/L) | 1.7 ± 0.3 | 1.6 ± 0.2 | 2.8 ± 0.3∗ | 3.6 ± 0.4∗∗ | 4.5 ± 0.5∗∗∗ |
| MCP-4 (ng/mL) | 41.9 ± 4.2 | 42.0 ± 4.1 | 49.7 ± 5.0∗ | 58.5 ± 5.9∗∗ | 66.3 ± 6.6∗∗∗ |
| AA (mg/L) | 35.2 ± 3.5 | 36.1 ± 3.6 | 44.2 ± 4.3∗ | 57.0 ± 5.6∗∗ | 65.2 ± 6.5∗∗∗ |
| hs-CRP (mg/L) | 2.7 ± 0.3 | 2.6 ± 0.4 | 3.9 ± 0.4∗ | 5.6 ± 0.6∗∗ | 6.5 ± 0.7∗∗∗ |
| TNF- | 20.1 ± 2.0 | 21.3 ± 2.1 | 29.4 ± 2.9∗ | 45.7 ± 4.6∗∗ | 50.6 ± 5.1∗∗∗ |
RCCAS: right common carotid artery stenosis; CON: control; MI-RCCAS: mild right common carotid artery stenosis; MO-RCCAS: moderate right common carotid artery stenosis; SE-RCCAS: severe right common carotid artery stenosis; TOS: total oxidant status; LHP: lipid hydroperoxide; 8-IP: 8-isoprostane; MDA: malondialdehyde; MCP-4: monocyte chemotactic protein-4; AA: amyloid A; hs-CRP: high-sensitivity C-reactive protein; TNF-α: tumor necrosis factor-α. P > 0.05 (CON group/no carotid stenosis group). ∗P < 0.001 (no carotid stenosis group/MI-RCCAS group). ∗∗P < 0.001 (MI-RCCAS group/MO-RCCAS group). ∗∗∗P < 0.001 (MO-RCCAS group/SE-RCCAS group). Group comparisons (CON group/no carotid stenosis group/MI-RCCAS group/MO-RCCAS group/SE-RCCAS group) were made using ANOVA, P < 0.001.
Levels of biomarkers in patients with RECAS.
| CON ( | No carotid stenosis ( | MI-RECAS ( | MO-RECAS ( | SE-RECAS ( | |
|---|---|---|---|---|---|
| TOS ( | 7.3 ± 0.7 | 7.4 ± 0.7 | 8.9 ± 0.9∗ | 10.0 ± 1.2∗∗ | 12.1 ± 1.3∗∗∗ |
| LHP ( | 5.8 ± 0.6 | 5.9 ± 0.6 | 7.0 ± 0.7∗ | 8.5 ± 0.9∗∗ | 9.7 ± 2.3∗∗∗ |
| 8-IP (pg/mL) | 45.2 ± 4.5 | 45.0 ± 4.4 | 59.7 ± 6.0∗ | 65.2 ± 6.4∗∗ | 82.0 ± 7.8∗∗∗ |
| MDA (nmol/L) | 1.7 ± 0.3 | 1.6 ± 0.2 | 3.8 ± 0.5∗ | 4.9 ± 0.6∗∗ | 7.2 ± 0.8∗∗∗ |
| MCP-4 (ng/mL) | 41.9 ± 4.2 | 42.0 ± 4.2 | 59.6 ± 6.0∗ | 78.5 ± 7.9∗∗ | 96.3 ± 8.9∗∗∗ |
| AA (mg/L) | 35.2 ± 3.5 | 36.1 ± 3.6 | 54.1 ± 5.3∗ | 75.0 ± 7.3∗∗ | 96.2 ± 8.7∗∗∗ |
| hs-CRP (mg/L) | 2.7 ± 0.3 | 2.6 ± 0.3 | 4.4 ± 0.5∗ | 6.9 ± 0.6∗∗ | 8.5 ± 0.7∗∗∗ |
| TNF- | 20.1 ± 2.0 | 21.3 ± 2.1 | 40.4 ± 3.9∗ | 69.7 ± 7.0∗∗ | 88.6 ± 9.1∗∗∗ |
RECAS: right external carotid artery stenosis; CON: control; MI-RECAS: mild right external carotid artery stenosis; MO-RECAS: moderate right external carotid artery stenosis; SE-RECAS: severe right external carotid artery stenosis; TOS: total oxidant status; LHP: lipid hydroperoxide; 8-IP: 8-isoprostane; MDA: malondialdehyde; MCP-4: monocyte chemotactic protein-4; AA: amyloid A; hs-CRP: high-sensitivity C-reactive protein; TNF-α: tumor necrosis factor-α. P > 0.05 (CON group/no carotid stenosis group). ∗P < 0.001 (no carotid stenosis group/MI-RECAS group). ∗∗P < 0.001 (MI-RECAS group/MO-RECAS group). ∗∗∗P < 0.001 (MO-RECAS group/SE-RECAS group). Group comparisons (CON group/no carotid stenosis group/MI-RECAS group/MO-RECAS group/SE-RECAS group) were made using ANOVA, P < 0.001.
Levels of biomarkers in patients with RICAS.
| CON ( | No carotid stenosis ( | MI-RICAS ( | MO-RICAS ( | SE-RICAS ( | |
|---|---|---|---|---|---|
| TOS ( | 7.3 ± 0.7 | 7.4 ± 0.7 | 13.7 ± 1.4∗ | 18.0 ± 2.0∗∗ | 26.9 ± 3.0∗∗∗ |
| LHP ( | 5.8 ± 0.6 | 5.9 ± 0.6 | 7.9 ± 0.7∗ | 11.5 ± 1.2∗∗ | 12.7 ± 1.4∗∗∗ |
| 8-IP (pg/mL) | 45.2 ± 4.5 | 45.0 ± 4.4 | 69.7 ± 7.0∗ | 95.0 ± 9.2∗∗ | 106.4 ± 10.3∗∗∗ |
| MDA (nmol/L) | 1.7 ± 0.3 | 1.6 ± 0.2 | 3.8 ± 0.4∗ | 6.5 ± 1.3∗∗ | 9.2 ± 1.2∗∗∗ |
| MCP-4 (ng/mL) | 41.9 ± 4.2 | 42.0 ± 4.2 | 69.7 ± 7.0∗ | 88.5 ± 8.2∗∗ | 116.3 ± 11.6∗∗∗ |
| AA (mg/L) | 35.2 ± 3.5 | 36.1 ± 3.6 | 54.1 ± 5.9∗ | 85.0 ± 9.0∗∗ | 109.2 ± 10.3∗∗∗ |
| hs-CRP (mg/L) | 2.7 ± 0.3 | 2.6 ± 0.3 | 5.2 ± 0.5∗ | 7.9 ± 0.8∗∗ | 11.0 ± 1.1∗∗∗ |
| TNF- | 20.1 ± 2.0 | 21.3 ± 2.1 | 50.4 ± 5.3∗ | 79.7 ± 8.0∗∗ | 98.6 ± 9.2∗∗∗ |
RICAS: right internal carotid artery stenosis; CON: control; MI-RICAS: mild right internal carotid artery stenosis; MO-RICAS: moderate right internal carotid artery stenosis; SE-RICAS: severe right internal carotid artery stenosis; TOS: total oxidant status; LHP: lipid hydroperoxide; 8-IP: 8-isoprostane; MDA: malondialdehyde; MCP-4: monocyte chemotactic protein-4; AA: amyloid A; hs-CRP: high-sensitivity C-reactive protein; TNF-α: tumor necrosis factor-α. P > 0.05 (CON group/no carotid stenosis group). ∗P < 0.001 (no carotid stenosis group/MI-RICAS group). ∗∗P < 0.001 (MI-RICAS group/MO-RICAS group). ∗∗∗P < 0.001 (MO-RICAS group/SE-RICAS group). Group comparisons (CON group/no carotid stenosis group/MI-RICAS group/MO-RICAS group/SE-RICAS group) were made using ANOVA, P < 0.001.
Levels of biomarkers in patients with carotid artery severe stenosis.
| CON ( | No carotid stenosis ( | SE-RCCAS+SE-RECAS ( | SE-RCCAS+SE-RICAS ( | SE-RCCAS+SE-RECAS+SE-RICAS ( | |
|---|---|---|---|---|---|
| TOS ( | 7.3 ± 0.7 | 7.4 ± 0.7 | 17.3 ± 1.6∗ | 33.9 ± 2.4∗∗ | 46.9 ± 3.6∗∗∗ |
| LHP ( | 5.8 ± 0.6 | 5.9 ± 0.6 | 11.7 ± 1.2∗ | 18.3 ± 1.6∗∗ | 24.7 ± 2.3∗∗∗ |
| 8-IP (pg/mL) | 45.2 ± 4.5 | 45.0 ± 4.4 | 73.7 ± 7.3∗ | 115.0 ± 10.5∗∗ | 146.4 ± 13.6∗∗∗ |
| MDA (nmol/L) | 1.7 ± 0.3 | 1.6 ± 0.2 | 4.0 ± 0.4∗ | 7.5 ± 0.6∗∗ | 10.2 ± 0.9∗∗∗ |
| MCP-4 (ng/mL) | 41.9 ± 4.2 | 42.0 ± 4.2 | 79.7 ± 6.8∗ | 138.5 ± 12.8∗∗ | 176.3 ± 16.4∗∗∗ |
| AA (mg/L) | 35.2 ± 3.5 | 36.1 ± 3.6 | 60.9 ± 5.9∗ | 86.0 ± 7.6∗∗ | 110.2 ± 10.1∗∗∗ |
| hs-CRP (mg/L) | 2.7 ± 0.3 | 2.6 ± 0.3 | 5.4 ± 0.4∗ | 8.4 ± 0.6∗∗ | 12.0 ± 0.9∗∗∗ |
| TNF- | 20.1 ± 2.0 | 21.3 ± 2.1 | 49.4 ± 3.9∗ | 79.7 ± 6.5∗∗ | 118.6 ± 10.8∗∗∗ |
CON: control; SE-RCCAS: severe right common carotid artery stenosis; SE-RECAS: severe right external carotid artery stenosis; SE-RICAS: severe right internal carotid artery stenosis; TOS: total oxidant status; LHP: lipid hydroperoxide; 8-IP: 8-isoprostane; MDA: malondialdehyde; MCP-4: monocyte chemotactic protein-4; AA: amyloid A; hs-CRP: high-sensitivity C-reactive protein; TNF-α: tumor necrosis factor-α. P > 0.05 (CON group/no carotid stenosis group). ∗P < 0.001 (no carotid stenosis group/SE-RCCAS+SE-RECAS group). ∗∗P < 0.001 (SE-RCCAS+SE-RECAS group/SE-RCCAS+SE-RICAS group). ∗∗∗P < 0.001 (SE-RCCAS+SE-RICAS group/SE-RCCAS+SE-RECAS+SE-RICAS group). Group comparisons (CON group/no carotid stenosis group/SE-RCCAS+SE-RECAS group/SE-RCCAS+SE-RICAS group/SE-RCCAS+SE-RECAS+SE-RICAS group) were made using ANOVA, P < 0.001.
Levels of biomarkers in patients with carotid artery severe stenosis and severe coronary artery stenosis.
| CON ( | No carotid stenosis ( | SE-RCCAS+SOVCS ( | SE-RECAS+STVCS ( | SE-RICAS+SMVCS ( | |
|---|---|---|---|---|---|
| TOS ( | 7.3 ± 0.7 | 7.4 ± 0.7 | 18.6 ± 1.5∗ | 39.0 ± 3.6∗∗ | 48.9 ± 4.5∗∗∗ |
| LHP ( | 5.8 ± 0.6 | 5.9 ± 0.6 | 12.0 ± 0.9∗ | 19.5 ± 2.0∗∗ | 28.6 ± 3.1∗∗∗ |
| 8-IP (pg/mL) | 45.2 ± 4.5 | 45.0 ± 4.4 | 83.9 ± 7.2∗ | 135.0 ± 12.5∗∗ | 159.4 ± 14.8∗∗∗ |
| MDA (nmol/L) | 1.7 ± 0.3 | 1.6 ± 0.2 | 5.8 ± 0.4∗ | 9.0 ± 0.7∗∗ | 11.3 ± 1.2∗∗∗ |
| MCP-4 (ng/mL) | 41.9 ± 4.2 | 42.0 ± 4.2 | 87.9 ± 7.9∗ | 149.5 ± 13.2∗∗ | 190.3 ± 18.6∗∗∗ |
| AA (mg/L) | 35.2 ± 3.5 | 36.1 ± 3.6 | 64.1 ± 5.4∗ | 86.0 ± 7.4∗∗ | 120.2 ± 11.3∗∗∗ |
| hs-CRP (mg/L) | 2.7 ± 0.3 | 2.6 ± 0.3 | 5.9 ± 0.5∗ | 10.4 ± 0.9∗∗ | 14.5 ± 1.3∗∗∗ |
| TNF- | 20.1 ± 2.0 | 21.3 ± 2.1 | 53.4 ± 5.2∗ | 99.7 ± 10.1∗∗ | 140.6 ± 13.0∗∗∗ |
CON: control; SE-RCCAS: severe right common carotid artery stenosis; SOVCS: severe one-vessel coronary stenosis; SE-RECAS: severe right external carotid artery stenosis; STVCS: severe two-vessel coronary stenosis; SE-RICAS: severe right internal carotid artery stenosis; SMVCS: severe multivessel coronary stenosis; TOS: total oxidant status; LHP: lipid hydroperoxide; 8-IP: 8-isoprostane; MDA: malondialdehyde; MCP-4: monocyte chemotactic protein-4; AA: amyloid A; hs-CRP: high-sensitivity C-reactive protein; TNF-α: tumor necrosis factor-α. P > 0.05 (CON group/no carotid stenosis group). ∗P < 0.001 (no carotid stenosis group/SE-RCCAS+OVCS group). ∗∗P < 0.001 (SE-RCCAS+OVCS group/SE-RECAS+TVCS group). ∗∗∗P < 0.001 (SE-RECAS+TVCS group/SE-RICAS+MVCS group). Group comparisons (CON group/no carotid stenosis group/SE-RCCAS+OVCS group/SE-RECAS+TVCS group/SE-RICAS+MVCS group) were made using ANOVA, P < 0.001.
The incidences of severe right carotid stenosis and coronary artery stenosis.
| Age groups (years) | MI-RCS ( | MO-RCS ( | SE-RAS ( | SE-RAS+SMVCS ( |
|---|---|---|---|---|
| 65-70, | 80 (47.0) | 70 (41.7) | 40 (24.0) | 22 (20.7) |
| 75-80, | 60 (34.2)∗ | 50 (33.2)∗ | 50 (33.1)∗ | 31 (32.2)∗ |
| 81-86, | 30 (18.6)∗∗ | 40 (25.0)∗∗ | 76 (42.7)∗∗ | 53 (47.0)∗∗ |
MI-RCS: mild right carotid stenosis; MO-RCS: moderate right carotid stenosis; SE-RAS: severe right arotid stenosis; SE-RAS+SMVCS: severe right arotid stenosis+severe multivessel coronary stenosis. ∗P < 0.05 (65-70 age group/75-80 age group). ∗∗P < 0.05 (75-80 age group/81-86 age group). Group comparisons (65-70 age group/75-80 age group/81-86 age group) were made using ANOVA, P <0.05.
Multiple regression analysis to evaluate risk predictors for carotid and coronary artery stenosis.
| TOS | 5.30 | 1.45-18.65 | 0.002 |
|---|---|---|---|
| LHP | 3.19 | 1.32-2.97 | 0.01 |
| 8-IP | 2.50 | 1.30-3.14 | 0.04 |
| MDA | 4.78 | 1.46-19.86 | 0.001 |
| MCP-4 | 2.36 | 1.35-4.20 | 0.03 |
| AA | 3.07 | 1.31-2.99 | 0.04 |
| Hs-CRP | 4.92 | 1.62-12.05 | 0.001 |
| TNF- | 5.81 | 1.49-19.83 | 0.001 |
TOS: total oxidant status; LHP: lipid hydroperoxide; 8-IP: 8-isoprostane; MDA: malondialdehyde; MCP-4: monocyte chemotactic protein-4; AA: amyloid A; hs-CRP: high-sensitivity C-reactive protein; TNF-α: tumor necrosis factor-α.